LY2090314,英文名:LY2090314,CAS:603288-22-8,化学式:C28H25FN6O3,分子量:512.53,密度:1.55±0.1 g/cm3(Predicted),MSDS

cript> $(function () { var content = $(".refs").html(); var more = true; //限制字符个数 var hide = function () { $(".refs").each(function () { var maxheight = 120; if ($(this).text().length > maxheight) { $(this).text($(this).text().substring(0, maxheight)); $(this).html($(this).html() + '...'); more = true; $('.more').html("查看更多"); } else { $('.more').hide(); } }); }; hide(); $('.more').click(function () { if (more) { $(".refs").html(content); $(this).html("收起"); more = false; } else { hide(); } }); }) cript>

603288-22-8 询问

LY2090314(LY2090314)

CAS: 603288-22-8

化学式: C28H25FN6O3

<"" ="xl" ""> cript> function qrload() { var head = document.getElementsByTagName('HEAD').item(0); var script = document.createElement('SCRIPT'); script.src = "https://www.chembk.com/assets/js/qrcode.min.js"; script.type = "text/javascript"; head.appendChild(script); } function qrcode() { var url = window.location.href; var qrcode = new QRCode(document.getElementById("qrcode"), { width: 200, height: 200, useSVG: true }); qrcode.makeCode(url); } cript>

中文名	LY2090314
英文名	LY2090314
别名	GSK-3抑制剂 GSK-3抑制剂(LY2090314)
英文别名	CS-843 LY2090314 LY 2090314 LY-2090314 3-(9-fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione 7-(2,5-Dihydro-4-imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-9-fluoro-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)pyrrolo[3,2,1-jk][1,4]benzodiazepine 7-(2,5-Dihydro-4-imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-9-fluoro-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)pyrrolo[3,2,1-jk][1,4]benzodiazepine LY2090314
CAS	603288-22-8
化学式	C28H25FN6O3
分子量	512.53
密度	1.55±0.1 g/cm3(Predicted)
溶解度	溶于DMSO，不溶于水
酸度系数	7.41±0.60(Predicted)
存储条件	-20°C
外观	粉末
颜色	yellow to orange
靶点	GSK-3α GSK-3β
体外研究	LY2090314通过阻断ATP结合选择性抑制GSK-3的活性。LY2090314能够稳定β-连环蛋白。LY2090314单药治疗，表现出有限的疗效。LY3090314增强顺铂和卡铂对体外实体肿瘤癌细胞系的疗效。 LY2090314通过阻断ATP结合选择性抑制GSK-3的活性。LY2090314能够稳定β-连环蛋白。LY2090314单药治疗，表现出有限的疗效。LY3090314增强顺铂和卡铂对体外实体肿瘤癌细胞系的疗效。
体内研究	LY3090314增强顺铂和卡铂对体外实体肿瘤癌细胞系的疗效。 LY2090314增强顺铂和卡铂对 异种移植 的 实体肿瘤的 疗效。
参考资料 展开查看	1. Zamek-Gliszczynski MJ, et al. Pharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: a case study in rapid clearance by extensive metabolism with low circulating metabolite exposure. Dr2. Atkinson JM, et al. Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3. PLoS One. 2015 Apr 27;10(4):e0125028.

603288-22-8 - 配置溶液浓度参考

	1mg	5mg	10mg
1 mM	1.951 ml	9.756 ml	19.511 ml
5 mM	0.39 ml	1.951 ml	3.902 ml
10 mM	0.195 ml	0.976 ml	1.951 ml
5 mM	0.039 ml	0.195 ml	0.39 ml

最后更新：2024-01-02 23:10:35